Search
Search
Close this search box.

Cultivating Precision: Medocann’s Vision for Ultra-Premium Craft Cannabis on the Global Stage

In today’s crowded cannabis landscape, where “premium” is often used as a buzzword, The Medocann Group is setting a higher bar. Founded on nearly a century of family farming heritage and powered by state-of-the-art biotechnology, the Israeli company is redefining what premium truly means: consistency, purity, and precision at every stage of cultivation.

As part of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub we speak with Asaf Sella, Co-Founder and CEO, and Narkis Tessler, Chief of Strategy and Business Development, about Medocann’s philosophy, the technology behind their SMART indoor facility, and how they’re building long-term partnerships to take their craft cannabis to the global stage.

From pesticide-free cultivation and small-batch craftsmanship to patient loyalty and strategic international expansion, the discussion explores how Medocann is combining legacy, science, and vision to shape the future of ultra-premium cannabis.


 

Farming Meets Precision Engineering

“We approach cultivation not as farming alone, but as precision-driven biotechnology,” explains Asaf Sella, Co-Founder and CEO of Medocann. “Our SMART indoor facility is designed to maintain total environmental control — light, humidity, airflow, nutrients — allowing us to cultivate with zero pesticides and zero compromise.”

Unlike traditional greenhouse or hybrid set-ups, Medocann’s closed-loop indoor system ensures uniformity across every batch, every time. The team leverages data analytics, advanced automation, and real-time plant monitoring to optimize for potency, terpene retention, and cleanliness. The result? Predictable excellence, backed by rigorous quality assurance protocols and built to EU-GMP standards.

Beyond “Premium” — A New Global Standard

Medocann’s products are anything but off-the-shelf. The company cultivates in small batches, hand-trims every flower, and slow-cures each harvest to protect the delicate trichomes holding the cannabinoid and terpene profile of each cultivar. This care is reflected in its two signature lines: SEVEN, a therapeutic-grade collection trusted by Israeli patients and clinicians, and SOLO, an ultra-premium craft collection for cannabis connoisseurs.

“There’s a lot of talk about premium in this space, but for us, it’s a discipline,” says Sella. “Every decision — from phenohunting to post-harvest handling — is made to serve the integrity of the plant and the experience of the consumer.”

Strategic Global Expansion with Select Partners

With a mature domestic footprint in Israel — one of the most regulated and quality-driven cannabis markets globally — Medocann is now actively expanding its international presence.

“Our focus is on long-term partnerships with top-tier distributors who recognise the value of consistency, differentiation, and trust,” says Narkis Tessler, Chief of Strategy and Business Development. “We’re not looking to be just another supplier — we’re seeking partners who are committed to building long-term brand equity in the ultra-premium cannabis space.”

Known for their consistency and efficacy, Medocann’s SEVEN products quickly earn patient loyalty — driving repeat demand and helping partners build a strong, premium presence in their markets.

A Future Built on Integrity, Innovation, and Trust

As regulatory frameworks evolve and consumer expectations sharpen, Medocann believes the cannabis industry is entering its quality-first era.

“We see cannabis moving from commodity to connoisseurship,” says Tessler. “The future belongs to companies that can consistently deliver safety, efficacy, and elevated experiences — not just once, but every single time.”

With its SMART indoor facility, pesticide-free commitment, and a growing international footprint, The Medocann Group is ready to meet that future — and help shape it.

 

 

Interested in partnering with Medocann? Visit www.medocann.com or contact us (info@medocann.com) to explore how we can bring ultra-premium craft cannabis to your market — together.

⏰ Pre-order discount ends Jan 15
-- Days
-- Hours
-- Mins
Data packs delivered January 2026
🔬 New Report Due January 2026

Global Medical Cannabis Market Review 2026

A comprehensive analysis of the international medical cannabis supply chain — examining country-specific data on exports, imports, market size, domestic production, and distribution landscapes. Understand the driving forces behind global supply dynamics, the impact of telemedicine on patient access, and regulatory changes shaping the market.

What's covered

  • 📊 Global supply chain overview — understand export/import dynamics and domestic production capabilities
  • 🌍 8 export country snapshots — Canada, Portugal, Denmark, North Macedonia, Spain, Australia, Czech Republic, South Africa
  • 👥 6 patient market snapshots — Australia, Germany, UK, Poland, Brazil, France
  • 🔮 Key themes — Canada's global impact, telemedicine growth, new market openings, quota changes
Export Markets
🇨🇦 Canada 🇵🇹 Portugal 🇩🇰 Denmark 🇲🇰 N. Macedonia 🇪🇸 Spain 🇦🇺 Australia 🇨🇿 Czechia 🇿🇦 South Africa
Patient Markets
🇦🇺 Australia 🇩🇪 Germany 🇬🇧 UK 🇵🇱 Poland 🇧🇷 Brazil 🇫🇷 France
100% free • No credit card required
As trusted by
DIAGEO KPMG Coca-Cola BARCLAYS BNP PARIBAS AB InBev NOVARTIS Johnson & Johnson PEPSICO AXA POLITICO Bloomberg amazon CNN Business
Part of our annual market review series GDPR compliant

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?